Skip to main content

Table 4 Univariate and multivariate COX regression analyses for patients with isolated distant lymph node metastases

From: Site-specific metastases of gallbladder adenocarcinoma and their prognostic value for survival: a SEER-based study

Features

Overall survival

Cancer specific survival

Univariate

Multivariate

Univariate

Multivariate

HR (95% CI)

P-value

HR (95% CI)

P-value

HR (95% CI)

P-value

HR (95% CI)

P-value

Age

 < 60

1.000 (Reference)

   

1.000 (Reference)

   

 60–69

0.761 (0.393–1.472)

0.416

  

0.755 (0.390–1.463)

0.405

  

 70–79

1.054 (0.554–2.006)

0.872

  

0.957 (0.497–1.845)

0.897

  

 ≥ 80

1.695 (0.691–4.160)

0.249

  

1.726 (0.703–4.239)

0.234

  

Gender

 Male

1.000 (Reference)

   

1.000 (Reference)

   

 Female

0.747 (0.453–1.232)

0.254

  

0.710 (0.429–1.177)

0.184

  

Marriage

 Married

1.000 (Reference)

   

1.000 (Reference)

   

 Unmarried

0.615 (0.363–1.042)

0.071

  

0.645 (0.379–1.097)

0.106

  

 Unknown

1.133 (0.348–3.691)

0.836

  

1.208 (0.370–3.944)

0.755

  

Race

 White

1.000 (Reference)

   

1.000 (Reference)

   

 Black

0.491 (0.225–1.071)

0.074

  

0.510 (0.233–1.115)

0.091

  

 Others

0.741 (0.377–1.457)

0.385

  

0.770 (0.391–1.518)

0.450

  

Grade

 I

1.000 (Reference)

   

1.000 (Reference)

   

 II

0.466 (0.102–2.132)

0.325

  

0.466 (0.102–2.133)

0.325

  

 III + IV

1.133 (0.257–4.985)

0.869

  

1.061 (0.240–4.700)

0.938

  

 Unknown

1.465 (0.350–6.129)

0.601

  

1.436 (0.343–6.015)

0.621

  

T stage

 T0

1.000 (Reference)

   

1.000 (Reference)

   

 T1

0.513 (0.114–2.309)

0.385

  

0.510 (0.113–2.297)

0.381

  

 T2

0.340 (0.087–1.328)

0.121

  

0.330 (0.084–1.295)

0.112

  

 T3

0.483 (0.145–1.612)

0.237

  

0.441 (0.132–1.481)

0.185

  

 T4

0.788 (0.202–3.070)

0.731

  

0.785 (0.201–3.062)

0.728

  

 TX

0.946 (0.272–3.286)

0.930

  

0.943 (0.271–3.278)

0.926

  

N stage

 N0

1.000 (Reference)

   

1.000 (Reference)

   

 N1

0.623 (0.315–1.229)

0.172

  

0.610 (0.303–1.229)

0.167

  

 N2

0.757 (0.417–1.375)

0.360

  

0.794 (0.433–1.455)

0.455

  

 NX

0.705 (0.278–1.787)

0.461

  

0.738 (0.289–1.885)

0.525

  

Surgery at primary site

 Yes

1.000 (Reference)

 

1.000 (Reference)

 

1.000 (Reference)

 

1.000 (Reference)

 

 No

2.410 (1.389–4.181)

0.002

3.575 (1.968–6.494)

< 0.001

2.326 (1.335–4.053)

0.003

3.435 (1.883–6.268)

< 0.001

Radiation

 Yes

1.000 (Reference)

   

1.000 (Reference)

   

 No

2.061 (0.799–5.321)

0.135

  

2.020 (0.781–5.224)

0.147

  

Chemotherapy

 Yes

1.000 (Reference)

 

1.000 (Reference)

 

1.000 (Reference)

 

1.000 (Reference)

 

 No

2.426 (1.464–4.019)

0.001

3.667 (2.108–6.377)

< 0.001

2.421 (1.449–4.045)

0.001

3.622 (2.065–6.353)

< 0.001

Tumor size

 < 3 cm

1.000 (Reference)

   

1.000 (Reference)

   

 < 5 cm

1.649 (0.588–4.621)

0.342

  

1.675 (0.597–4.701)

0.327

  

 ≥ 5 cm

1.234 (0.474–3.215)

0.667

  

1.143 (0.434–3.011)

0.786

  

 Unknown

2.494 (1.032–6.024)

0.042

  

2.457 (1.014–5.954)

0.046

  
  1. Other races include Asian or Pacific Islander and American Indian/Alaska Native; Grade I = well differentiated, II = moderately differentiated, III = poorly differentiated, IV = undifferentiated; HR = hazard ratio; CI = confidence interval